Table 3

WBC PAH-DNA adduct levels for mothers and newborns by CYP1A1 and GSTP1 genotypes analyzed separatelya

GenotypeMaternal Mean ± SD per 108 nucleotides (n)bNewborn Mean ± SD per 108 nucleotides (n)b
Total6.4 ± 9.2 (135)7.6 ± 9.6 (135)
CYP1A1 MSPI RFLP
Group I: MspI restriction site absent6.9 ± 10.1 (107)7.0 ± 8.9 (106)d
Group II: MspI restriction site presentc4.7 ± 4.3 (21)9.8 ± 11.7 (28)
GSTP1
Group I: val/val7.4 ± 10.8 (15)3.5 ± 3.6 (16)e,f
Group II: ile/val7.0 ± 10.4 (54)8.9 ± 10.2 (70)
Group III: ile/ile5.9 ± 8.0 (60)7.7 ± 10.2 (42)
  • a Maternal adduct levels are stratified by the mother’s genotype, and newborn adduct levels are stratified by the newborn’s genotype; all models are controlled for place of residence, cigarette smoking, dietary PAHs, use of coal stoves for residential heating, and home/occupational exposures. Associations of borderline significance (0.1 > P > 0.05) are reported but are considered statistically significant at P ≤ 0.05.

  • b Number of subjects.

  • c Homozygotes and heterozygotes combined.

  • d Newborn CYP1A1 group I versus group II (P = 0.06).

  • e Newborn GSTP1 group I versus group II newborns (P = 0.07).

  • f Newborn GSTP1 group I versus group II + group III (P = 0.08).